Design Therapeutics DSGN
- Market cap
- $635.2M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- −8.7%
Design Therapeutics' trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| R&D | $13.3M−7% | $11M−23% | $9.8M−38% | $10.5M−38% | $11.9M−10% | $12.2M+10% | $15.4M+57% | $15.7M+50% | $14.6M+23% | $13.4M+10% | $14.4M−7% | $16.4M+4% |
| SG&A | $5.6M+14% | $4.1M−20% | $4.6M−22% | $4.5M−18% | $4.4M−22% | $4.5M+10% | $5M+10% | $5.8M+29% | $4.7M+8% | $4.7M+5% | $5.3M+6% | $5.8M−1% |
| −$18.8M−2% | −$15.1M−22% | −$14.4M−34% | −$15M−33% | −$16.2M−14% | −$16.7M+10% | −$20.4M+42% | −$21.6M+43% | −$19.3M+19% | −$18.2M+9% | −$19.7M−4% | −$22.2M+3% | |
| Net income | −$15.8M−11% | −$11.8M−32% | −$11.1M−42% | −$11.8M−41% | −$13M−17% | −$13.7M+15% | −$17.7M+60% | −$19.1M+62% | −$17M+30% | −$16M+17% | −$17.6M−0% | −$20.2M+6% |
| −$0.28−13% | −$0.21−32% | −$0.20−43% | −$0.21−42% | −$0.23−18% | −$0.24+14% | −$0.31+55% | −$0.34+62% | −$0.30+30% | −$0.27+13% | −$0.29−7% | −$0.32−6% | |
| 56M+0% | 56.1M+0% | 56.5M+1% | 56.6M+1% | 56.6M+1% | 56.7M+1% | 56.8M+1% | 56.9M+1% | 57M+1% | 58.7M+4% | 61.4M+8% | 62.5M+10% |
EPS, diluted: 5 periods, Q4 FY21 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 5 periods, Q4 FY21 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Design Therapeutics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| DSGNDesign Therapeutics | $635.2M | n/m | n/a | n/m | n/m | n/m | |
| ZVRAZevra Therapeutics | $599.8M | 10.9× | 12.2× | 4.4× | +119% | 42.8% | |
| IRWDIronwood Pharmaceuticals | $571.7M | 4.5× | 14.8× | 1.5× | +26% | 33.4% | |
| PBYIPuma Biotechnology | $525.5M | 19.6× | 12.3× | 2.3× | −3% | 11.6% | |
| COLLCollegium Pharmaceutical | $770.9M | 19.1× | 19.1× | 1.0× | +14% | 5.9% | |
| ABUSArbutus Biopharma | $791.4M | 5.1× | 5.6× | 4.4× | n/m | 84.2% | |
| ARVNArvinas | $491.7M | 47.0× | 50.5× | 1.6× | −15% | 2.9% | |
| CRMDCorMedix | $420.1M | 2.5× | 4.0× | 0.9× | +281% | 40.5% | |
| AMPHAmphastar Pharmaceuticals | $1.1B | 15.9× | 20.5× | 1.6× | +1% | 10.8% | |
| OMEROmeros | $1.3B | 11.7× | 11.7× | n/m | n/m | n/m | |
| ANABAnaptysbio | $1.4B | 10.3× | 99.3× | n/m | n/m | n/m | |
| Peer median | $685.3M | 11.3× | 13.5× | 1.6× | +14% | 22.5% |
More on Design Therapeutics
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .